Yuan Cheng

9PUBLICATIONS
5CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 28, 2026
Adjuvant Sintilimab Plus Bevacizumab After Curative Resection of Spontaneously Ruptured Hepatocellular Carcinoma: Protocol for a Prospective, Exploratory, Single-Arm Study (CLEAR-2).

|Jun 10, 2026
When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework.

|May 21, 2026
Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study.

|Feb 23, 2026
Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial.

Yuan Cheng, Jinguo Xia, Yongquan Chi

|Nov 03, 2025
Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.

Yuan Cheng, Feng Ye, Yongjun Chen

|Jul 30, 2025
Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial.

Yuan Cheng, Yaodong Zhang, Changxian Li

Pageof 2

Frequent Collaborators

2 joint publications

Feng Ye

1 joint publications

Ran You

1 joint publications

Jin Liu

1 joint publications

Xiao-Dong Zhu